2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2134 Long follow-up of a phase II study of ibrutinib versus ibrutinib plus rituximab in patients with high-risk chronic lymphocytic leukemia (CLL): 12-year update.

Ekaterina Kim, MS, PhD, Hyunsoo Hwang2, Gitanjali Jayachandran, PhD3, Xuelin Huang, PhD4, Thomas Mathew5, Mahesh Swaminathan, MD6, Nitin Jain, MD7, Alessandra Ferrajoli III, MD8, William G. Wierda, MD, PhD9, Jan A. Burger, MD, PhD10
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction: BTK inhibitors (BTKi) such as ibrutinib (Ibr) replaced chemo-immunotherapy for the treatment of chronic lymphocytic leukemia (CLL) based on improved survival outcomes, especially in patients with high-risk CLL. Data on long-term results in patients with CLL treated with BTKi-based therapy are limited. Here, we report the long-term outcome of an investigator-initiated phase 2 trial of ibrutinib with or without early rituximab (NCT02007044).

Methods: 208 patients with high-risk CLL, i.e. 181 patients with relapsed/refractory (R/R) CLL and 27 treatment-naïve (TN) patients with TP53 aberration, were randomized to receive Ibr 420 mg continuous daily (n = 104) or ibr 420 mg continuous daily with rituximab for the first 6 cycles (Ibr + R, n = 104) until disease progression or development of unacceptable toxicities. Patients were enrolled from Dec 2013 to Oct 2017 (Burger et al., Blood, 2019). Treatment arms were similar in long-term outcomes, and for this update they were analyzed together. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier method; measurable residual disease (MRD) was assessed by flow cytometry.

Results: At data cut-off, 176 patients (85%) were alive, and 26 patients (13%) remained on study. The most common reasons for treatment discontinuation were adverse events (n = 54, 26%) and disease progression (n = 54, 26%), including 7 cases (3.4%) of Richter transformation. After a median follow-up of 77 months (range, 3 – 143 months), the median PFS was 72 months, the estimated 5- and 10-year PFS were 60.7% and 24.6%, respectively. The median OS was not reached, and the estimated 5- and 10-year OS were 90.6% and 76.4%, respectively. In subgroup analyses, unmutated IGHV and del(17p)/TP53 mutation were not associated with shorter survival. Patients with TN CLL carrying del(17p)/TP53 mutation (n=27) had longer median PFS than patients with R/R CLL with TP53 aberrations (n=51) (75 months vs. 58 months); however, this difference was not statistically significant. Fifty-four patients (26.0%) achieved a CR/CRi as best response. Eleven patients (5.3%) achieved bone marrow undetectable MRD4 status, and 25 (12.0%) achieved blood undetectable MRD4 status as best response.

The most frequent AE of any grade was hypertension (55.3%), fatigue (45.7%), bruising (40.4%), arthralgia (36.5%), upper respiratory infection (34.1%), skin disorders (31.3%), diarrhea (29.3%), and cough (25.5%). 147 patients (70.7%) had Ibr dose reduction; 43 patients (20.7%) received 280 mg/day Ibr, and 104 (50%) received 140 mg/day as lowest dose. The median time to first dose reduction was 19 months (range, 0.3 – 105 months). The median average Ibr dose was 296 mg/day (interquartile range (IQR), 218 – 381 mg/day), corresponding to a median dose intensity of 70.1% (IQR, 51.9% – 90.7%). In landmark analyses at 6 and 12 months, dose reduction was not significantly associated with shorter PFS (HR 1.27, 95% CI 0.84–1.93; HR 1.23, 95% CI 0.86–1.77) whereas early treatment interruption (>7 days) was associated with shorter PFS (HR 2.15, 95% CI 1.46–3.15; HR 1.46, 95% CI 1.03–2.08).

Conclusions: Ibr, alone or combined with R, induced durable remissions in patients with high-risk CLL. Ibr dose reductions occurred in the majority of patients however no differences were noted in terms of PFS and OS in patients with and without Ibr dose reduction.

Jan A. Burger, MD, PhD: Pharmacyclics, AbbVie, BeiGene, AstraZeneca - Research Funding